RPS6KA1

Across TCGA pan-cancer cohorts, RPS6KA1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPS6KA1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RPS6KA1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RPS6KA1 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where RPS6KA1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS6KA1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−0.500	<.001	12	view →
PDAC	Male	III,IV	+0.590	<.001	9	view →
LSCC	Male	II,III,IV	−0.409	<.001	8	view →
HNSC	Male	II,III,IV	+0.359	<.001	8	view →
OV	All	All	+0.521	.014	2	view →
COAD	Female	III,IV	−0.164	.046	1	view →
LUAD	Male	All	−0.103	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPS6KA1–CCRCC

Open the CCRCC breakdown →